Hipertensión arterial y enfermedad de Alzheimer
dc.contributor.author
dc.date.accessioned
2013-02-15T11:59:41Z
dc.date.available
2013-02-15T11:59:41Z
dc.date.issued
2010
dc.identifier.issn
1137-1242
dc.identifier.uri
dc.description.abstract
Hypertension (HT) is the most prevalent cardiovascular risk factor associated with dementia and Alzheimer disease (AD). The evidence about the association within hight blood pressure (BP) level in the middle age and dementia and Alzheimer’s disease incidence in the advanced age has increased. Longitudinal studies show that in the previous years of onset AD, BP is similar or lower in the patients who develop AD with regard to those who not develop. When patients has developed AD the case is the same that the previous one. Most studies show that BP reduction is beneficious to prevent cognitive impairment, dementia and AD. Is spite of some discordant studies, health authorities recommend to treat isolated systolic HT with an ‘A’ evidence degree, level 1, to prevent AD. Animal experimentation prove different ways to act of antihypertensive drugs in the AD prevention and has established the pathophysiological bases in this relation, until now only showed through various clinical studies
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Editorial Glosa
dc.relation.ispartof
© Alzheimer. Realidades e investigación en demencia, 2010, núm. 45, p. 30-39
dc.relation.ispartofseries
Articles publicats (D-CM)
dc.rights
Tots els drets reservats
dc.subject
dc.title
Hipertensión arterial y enfermedad de Alzheimer
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.idgrec
013661